Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanBas CoTSE:4575 +3.94%34 EV-to-EBITDA is -10.80 as of Aug. 27, 2026. GuruFocus rates TSE:4575 with a GF Score™ of 34/100. Among 414 Biotechnology companies, CanBas Co ranks worse than 241545.65% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CanBas Co's enterprise value is 円14,672.01 Mil.
CanBas Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円-1,358.47 Mil. Therefore, CanBas Co's EV-to-EBITDA for today is -10.80.
The historical rank and industry rank for CanBas Co's EV-to-EBITDA or its related term are showing as below:
TSE:4575'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -32.49 Med: -8.15 Max: -2.09
Current: -10.8
During the past 13 years, the highest EV-to-EBITDA of CanBas Co was -2.09. The lowest was -32.49. And the median was -8.15.
TSE:4575's EV-to-EBITDA is ranked worse than 100% of 414
companies
in the Biotechnology industry
Industry Median: 13.54
vs TSE:4575: -10.80
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CanBas Co's share price for today is 円818.00.
CanBas Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-66.420.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for CanBas Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4575 vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, CanBas Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanBas Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CanBas Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CanBas Co's EV-to-EBITDA falls into.
CanBas Co's current Enterprise Value is 円14,672.01 Mil.
CanBas Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1,358.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanBas Co (TSE:4575) has a EV-to-EBITDA of -10.80 as of Aug. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CanBas Co. According to the industry distribution chart, CanBas Co ranks #999999 out of 414 companies in the Biotechnology industry.
Is CanBas Co's EV-to-EBITDA too high?
CanBas Co's current EV-to-EBITDA is -10.80. Based on the distribution chart, CanBas Co ranks #999999 out of 414 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CanBas Co has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does CanBas Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CanBas Co ranks #999999 out of 414 companies for EV-to-EBITDA. This places CanBas Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.54, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CanBas Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanBas Co's current EV-to-EBITDA is -10.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanBas Co stock overvalued right now?
CanBas Co (TSE:4575) has a current EV-to-EBITDA of -10.80. The current EV-to-EBITDA is -10.80. CanBas Co's overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For CanBas Co (TSE:4575), the current EV-to-EBITDA is -10.80 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CanBas Co Ltd focuses on the discovery and development of novel oncology drugs targeting the cell cycle. Its product, CBP501 the anticancer drug candidate is a modified synthetic peptide which enhances the efficacy of cisplatin without adding toxicity.
34GF Score
Get the complete analysis for TSE:4575
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4575 has been successfully added to your 
